Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

talimogene laherparepvec

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

- PMLiVE

Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

Immunoglobulin G4-related disease affects approximately 20,000 people in the US

- PMLiVE

Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

Regulatory submissions are expected to be complete in the first half of this year

- PMLiVE

Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links